HRP20100240T1 - Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus - Google Patents

Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus Download PDF

Info

Publication number
HRP20100240T1
HRP20100240T1 HR20100240T HRP20100240T HRP20100240T1 HR P20100240 T1 HRP20100240 T1 HR P20100240T1 HR 20100240 T HR20100240 T HR 20100240T HR P20100240 T HRP20100240 T HR P20100240T HR P20100240 T1 HRP20100240 T1 HR P20100240T1
Authority
HR
Croatia
Prior art keywords
seq
polypeptide
sequence
amino acid
immunogen
Prior art date
Application number
HR20100240T
Other languages
English (en)
Croatian (hr)
Inventor
S. Anderson Annaliesa
Ute Jansen Kathrin
Kelly Rosemarie
D. Schultz Loren
L. Montgomery Donna
L. Mcclements William
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34107815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100240(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of HRP20100240T1 publication Critical patent/HRP20100240T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HR20100240T 2003-07-24 2004-07-22 Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus HRP20100240T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48984003P 2003-07-24 2003-07-24
US52011503P 2003-11-14 2003-11-14
PCT/US2004/023523 WO2005009379A2 (en) 2003-07-24 2004-07-22 Polypeptides for inducing a protective immune response against staphylococcus aureus

Publications (1)

Publication Number Publication Date
HRP20100240T1 true HRP20100240T1 (hr) 2010-09-30

Family

ID=34107815

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100240T HRP20100240T1 (hr) 2003-07-24 2004-07-22 Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus

Country Status (23)

Country Link
US (2) US20060177462A1 (cg-RX-API-DMAC7.html)
EP (1) EP1651166B8 (cg-RX-API-DMAC7.html)
JP (1) JP2007502101A (cg-RX-API-DMAC7.html)
KR (1) KR20060065643A (cg-RX-API-DMAC7.html)
AT (1) ATE457737T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004258979B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0412799A (cg-RX-API-DMAC7.html)
CA (1) CA2532370A1 (cg-RX-API-DMAC7.html)
CY (1) CY1110028T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004025579D1 (cg-RX-API-DMAC7.html)
DK (1) DK1651166T3 (cg-RX-API-DMAC7.html)
ES (1) ES2342778T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20100240T1 (cg-RX-API-DMAC7.html)
IL (1) IL173253A0 (cg-RX-API-DMAC7.html)
IS (1) IS8213A (cg-RX-API-DMAC7.html)
MX (1) MXPA06000854A (cg-RX-API-DMAC7.html)
NO (1) NO20060898L (cg-RX-API-DMAC7.html)
NZ (2) NZ570750A (cg-RX-API-DMAC7.html)
PL (1) PL1651166T3 (cg-RX-API-DMAC7.html)
PT (1) PT1651166E (cg-RX-API-DMAC7.html)
RU (1) RU2337108C2 (cg-RX-API-DMAC7.html)
SI (1) SI1651166T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005009379A2 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1725575B1 (en) * 2004-02-18 2012-11-28 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2006059247A2 (en) * 2004-10-25 2006-06-08 The University Of Western Ontario VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
JP2009524428A (ja) * 2006-01-27 2009-07-02 メルク エンド カムパニー インコーポレーテッド スタヒロコッカス・アウレウスｏｒｆ０６５７ｎを標的とする抗原結合タンパク質
AU2008251982A1 (en) 2007-01-24 2008-11-20 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus epidermidis
ATE537839T1 (de) * 2007-05-04 2012-01-15 Martin Kroenke Impfstoff zum schutz gegen staphylococcus aureus auf der basis zellwandassoziierter proteine
MX2009012891A (es) * 2007-05-31 2009-12-10 Merck & Co Inc Proteinas de union a antigeno dirigidas a staphylococcus aureus orf0657n.
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
AU2008292897B2 (en) 2007-08-31 2015-01-22 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
AU2009319947A1 (en) 2008-11-26 2010-06-03 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
SI3281947T1 (sl) 2009-04-03 2020-07-31 The University Of Chicago Sestave in metode v zvezi z variantami proteina A (SPA)
DK2510947T3 (en) 2009-04-14 2016-03-21 Glaxosmithkline Biolog Sa Compositions for Immunization against Staphylococcus aureus.
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
MX373250B (es) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
EP3199177A1 (en) 2009-10-30 2017-08-02 GlaxoSmithKline Biologicals S.A. Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2544709A4 (en) * 2010-03-12 2014-01-08 Univ Pennsylvania METHOD FOR PREVENTING AND TREATING THE COLONIZATION OF STAPHYLOCOCCUS AUREUS AND THEIR INFECTIOUS DISEASES AND DISEASES
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
US8747858B2 (en) 2010-07-13 2014-06-10 Merck Sharp & Dohme Corp. Staphylococcus aureus surface protein SA1789 and protective vaccine based thereon
WO2012065034A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US20140363461A1 (en) 2011-09-01 2014-12-11 Fabio Bagnoli Adjuvanted formulations of staphylococcus aureus antigens
EP2773370A4 (en) 2011-10-31 2016-09-28 Merck Sharp & Dohme PROTECTIVE VACCINE BASED ON THE STAPHYLOCOCCUS AUREUS PROTEIN SA2451
CA2871880A1 (en) * 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
RU2015100656A (ru) 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
EP2872173A4 (en) 2012-07-10 2016-03-23 Merck Sharp & Dohme PROTECTIVE VACCINE BASED ON THE STAPHYLOCOCCUS AUREUS PROTEIN SA2493
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
CA2373221A1 (en) * 1999-05-03 2000-11-30 Yashwant M. Deo Human antibodies to staphylococcus aureus
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP2339344A1 (en) * 2001-06-15 2011-06-29 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
ES2322338T3 (es) * 2001-11-12 2009-06-19 Novo Nordisk A/S Purificacion de peptidos por medio de cromatografia de afinidad con iones metalicos.
ATE419005T1 (de) * 2001-12-11 2009-01-15 Merck & Co Inc Staphylococcus aureus exopolysaccharid und verfahren
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
EP2368570A3 (en) * 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins

Also Published As

Publication number Publication date
IS8213A (is) 2005-12-30
WO2005009379A3 (en) 2006-11-30
JP2007502101A (ja) 2007-02-08
CA2532370A1 (en) 2005-02-03
ATE457737T1 (de) 2010-03-15
SI1651166T1 (sl) 2010-06-30
AU2004258979B2 (en) 2007-12-06
IL173253A0 (en) 2006-06-11
BRPI0412799A (pt) 2006-09-26
US20060177462A1 (en) 2006-08-10
NZ570750A (en) 2009-12-24
ES2342778T3 (es) 2010-07-14
NO20060898L (no) 2006-04-24
EP1651166A2 (en) 2006-05-03
DK1651166T3 (da) 2010-05-31
PL1651166T3 (pl) 2010-08-31
RU2337108C2 (ru) 2008-10-27
EP1651166A4 (en) 2008-03-05
US20100247561A1 (en) 2010-09-30
NZ544542A (en) 2009-01-31
DE602004025579D1 (de) 2010-04-01
WO2005009379A2 (en) 2005-02-03
EP1651166B1 (en) 2010-02-17
MXPA06000854A (es) 2006-03-30
KR20060065643A (ko) 2006-06-14
PT1651166E (pt) 2010-04-23
CY1110028T1 (el) 2015-01-14
RU2006105498A (ru) 2006-09-10
AU2004258979A1 (en) 2005-02-03
EP1651166B8 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
HRP20100240T1 (hr) Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus
JP2007502101A5 (cg-RX-API-DMAC7.html)
PH12021550030A1 (en) Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof
JP2009540801A5 (cg-RX-API-DMAC7.html)
EP4410843A1 (en) Recombinant fusion protein derived from hr region of s2 protein of sars-cov-2 and application of recombinant fusion protein
WO2003083058A2 (en) Replikin peptides in rapid replication of glioma cells and in influenza epidemics
CA2395499A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
JP7146926B2 (ja) Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン
ES2366176T3 (es) Citocinas aviares novedosas y secuencias genéticas que codifican para las mismas.
RU2012147590A (ru) Пептиды cdca5 и содержащие их вакцины
IE871169L (en) Vaccine against varicella-zoster virus
JP2012517239A5 (cg-RX-API-DMAC7.html)
CN113603754B (zh) 一种水禽h5n8亚型流感病毒ha重组蛋白及其制备方法与应用
JPS59501866A (ja) 腸内ウイルスに対するワクチン接種に有用なポリペプチド
CN107698665B (zh) 一种抗病毒多肽、编码基因、载体、宿主菌及应用
TW200716166A (en) Lawsonia intracellularis immunological proteins
KR20210130664A (ko) 삼량체를 형성하는 코로나-19 바이러스 (COVID-19, Coronavirus Disease 2019)의 재조합 스파이크 단백질 및 식물에서의 상기 재조합 스파이크 단백질의 대량 생산 방법과 이를 기반으로하는 백신조성물 제조 방법
HRP20100340T1 (hr) Polipeptidi koji imaju antimikrobno djelovanje i polinukleotidi koji ih kodiraju
CN103352047A (zh) 旋毛虫肌幼虫es抗原基因疫苗及其制备方法
CN102241748A (zh) D29分枝杆菌噬菌体来源的pk34多肽及其应用
Shao et al. DNA fragment encoding human IL-1β 163–171 peptide enhances the immune responses elicited in mice by DNA vaccine against foot-and-mouth disease
CN1035126A (zh) 编码狂犬病毒糖蛋白的基因片段及用此片段制备狂犬病毒糖蛋白的方法
CN115850398A (zh) 新型冠状病毒奥密克戎系列变异株的多肽组合物及其应用
KR101127926B1 (ko) 해수어 이리도바이러스 항원성 펩타이드 및 이를 이용한 이리도바이러스 예방용 백신
CN110386965B (zh) 一种坦布苏病毒e蛋白b细胞表位及其编码基因和应用